Flavor of the week: antibiotics

Share this article:

AstraZeneca and Roche each entered collaborations to take on hospital infections.

As noted by PMLive, AstraZeneca's collaboration with the Agency for Science, Technology and Research to attack gram-negative infections appears somewhat at odds with the drugmaker's decision to scale back its infection R&D.

Roche announced Monday that it is pursuing antibiotic research with private drugmaker Polyphor, with which it will target pseudomonas aeruginosa, an infection which the companies say accounts for 10% of US hospital-acquired infections.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.